Literature DB >> 18719017

A novel subset of NK cells expressing high levels of inhibitory FcgammaRIIB modulating antibody-dependent function.

Charles-Antoine Dutertre1, Emmanuelle Bonnin-Gélizé, Karen Pulford, Dominique Bourel, Wolf-Herman Fridman, Jean-Luc Teillaud.   

Abstract

NK cells can kill antibody-coated target cells following engagement of FcgammaRIIIA, the major activating FcgammaR expressed by these cells. The presence of FcgammaRIIC (CD32C) has also been reported, but its contribution to the FcgammaR-dependent effector functions of NK cells remains debated. We demonstrate here that inhibitory FcgammaRIIB is also expressed by a small subset of CD56+/NKp46+ NK cells and can efficiently down-modulate their FcgammaR-dependent effector function. Immunofluorescence analyses of NK cells from 52 healthy donors showed the presence of CD56bright/FcgammaRII(-) (5.2%+/-3.4), CD56dim/FcgammaRII(lo/-) (94.1%+/-3.4), and CD56dim/FcgammaRIIbright (0.64%+/-0.72) cells. QRT-PCR and protein analyses performed on isolated FcgammaRIIbright NK cells indicated that FcgammaRIIB is strongly expressed by these cells but not by FcgammaRII(lo/-) cells. In addition, FcgammaRIIbright cells showed a weaker antibody-dependent degranulation when incubated with IgG-coated target cells compared with FcgammaRII(lo/-) NK cells, although a strong FcgammaRIIIA expression was detected in both cells. Furthermore, the addition of anti-FcgammaRII Fab paralleled a higher degranulation of FcgammaRIIbright NK cells, indicating a direct role for FcgammaRIIB in this down-modulating effect. Thus, it is proposed that FcgammaRIIBbright NK cells represent a new NK cell compartment able to down-modulate NK cell functions triggered by the engagement of activating FcgammaR.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18719017     DOI: 10.1189/jlb.0608343

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  18 in total

1.  Allelic-dependent expression of an activating Fc receptor on B cells enhances humoral immune responses.

Authors:  Xinrui Li; Jianming Wu; Travis Ptacek; David T Redden; Elizabeth E Brown; Graciela S Alarcón; Rosalind Ramsey-Goldman; Michelle A Petri; John D Reveille; Richard A Kaslow; Robert P Kimberly; Jeffrey C Edberg
Journal:  Sci Transl Med       Date:  2013-12-18       Impact factor: 17.956

2.  Circulating CD16+CD56+ nature killer cells indicate the prognosis of colorectal cancer after initial chemotherapy.

Authors:  Feng Cui; Di Qu; Ruya Sun; Kejun Nan
Journal:  Med Oncol       Date:  2019-09-06       Impact factor: 3.064

Review 3.  Three major uncertainties in the antibody therapy of cancer.

Authors:  George T Stevenson
Journal:  Haematologica       Date:  2014-10       Impact factor: 9.941

4.  Rituximab inhibits Kv1.3 channels in human B lymphoma cells via activation of FcγRIIB receptors.

Authors:  Li-Hua Wang; Ning Wang; Xiao-Yu Lu; Bing-Chen Liu; Murali K Yanda; John Z Song; Helena M Dai; Yu-Liang Sun; Hui-Fang Bao; Douglas C Eaton; He-Ping Ma
Journal:  Biochim Biophys Acta       Date:  2011-12-13

Review 5.  From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement.

Authors:  Loïs Coënon; Martin Villalba
Journal:  Front Immunol       Date:  2022-06-03       Impact factor: 8.786

Review 6.  Fc gamma receptors in respiratory syncytial virus infections: implications for innate immunity.

Authors:  Jop Jans; Marloes Vissers; Jacco G M Heldens; Marien I de Jonge; Ofer Levy; Gerben Ferwerda
Journal:  Rev Med Virol       Date:  2013-11-14       Impact factor: 6.989

7.  The CD3ζ adaptor structure determines functional differences between human and mouse CD16 Fc receptor signaling.

Authors:  Oscar A Aguilar; Lam-Kiu Fong; Kenichi Ishiyama; William F DeGrado; Lewis L Lanier
Journal:  J Exp Med       Date:  2022-03-23       Impact factor: 14.307

Review 8.  The Role of Natural Killer T Cells in Cancer-A Phenotypical and Functional Approach.

Authors:  Daniëlle Krijgsman; Marianne Hokland; Peter J K Kuppen
Journal:  Front Immunol       Date:  2018-02-27       Impact factor: 7.561

9.  Genomic pathology of SLE-associated copy-number variation at the FCGR2C/FCGR3B/FCGR2B locus.

Authors:  Michael Mueller; Paula Barros; Abigail S Witherden; Amy L Roberts; Zhou Zhang; Helmut Schaschl; Chack-Yung Yu; Matthew E Hurles; Catherine Schaffner; R Andres Floto; Laurence Game; Karyn Meltz Steinberg; Richard K Wilson; Tina A Graves; Evan E Eichler; H Terence Cook; Timothy J Vyse; Timothy J Aitman
Journal:  Am J Hum Genet       Date:  2012-12-20       Impact factor: 11.025

10.  Compromised NK cell-mediated antibody-dependent cellular cytotoxicity in chronic SIV/SHIV infection.

Authors:  Xuan He; Dan Li; Zhenwu Luo; Hua Liang; Hong Peng; Yangyang Zhao; Nidan Wang; Donghua Liu; Chuan Qin; Qiang Wei; Huimin Yan; Yiming Shao
Journal:  PLoS One       Date:  2013-02-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.